Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
Globe Newswire•04/08/2026•06:55 ET
0
Whiz Insights
Get started
Create a free account to read the full story.